Potential targets of Euodiae Fructus in treatment of insomnia based on network pharmacology.
10.19540/j.cnki.cjcmm.20210419.401
- Author:
Lei LI
1
;
Jing-Jing LU
1
;
Wei-Tao WANG
2
;
Na WANG
1
;
Li-Xiang WANG
2
;
Yan-Min MA
2
;
Shu LIU
1
Author Information
1. the First Affiliated Hospital of Henan University of Chinese Medicine Zhengzhou 450000, China.
2. Henan University of Chinese Medicine Zhengzhou 450000, China.
- Publication Type:Journal Article
- Keywords:
Euodiae Fructus;
berberine;
insomnia;
network pharmacology
- MeSH:
Animals;
Databases, Genetic;
Drugs, Chinese Herbal/pharmacology*;
Gene Ontology;
Humans;
Medicine, Chinese Traditional;
Mice;
Sleep Initiation and Maintenance Disorders/genetics*
- From:
China Journal of Chinese Materia Medica
2021;46(12):3016-3023
- CountryChina
- Language:Chinese
-
Abstract:
The acupoint application of Euodiae Fructus at Yongquan(KI1) can significantly improve the sleep quality of patients with insomnia with berberine as the main effective component for the efficacy. Nineteen active compounds and 203 drug targets were screened out from Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform(TCMSP). After comparison with GeneCards and Online Mendelian Inheritance in Man(OMIM), 24 common genes of diseases and drugs were obtained. STRING 11.0 was used to construct a protein-protein interaction(PPI) network of the overlapping genes, and Matthews correlation coefficient(MCC) was employed to screen the core genes, which were then subjected to enrichment analysis with gene ontology(GO) and Kyoto encyclopedia of genes and genomes(KEGG). The results revealed that the main compounds of Euodiae Fructus, such as berberine and rutaecarpine, participated in the biological processes(such as neurotransmitter receptor activity) by regulating C-reactive protein(CRP), estrogen receptor 1(ESR1), 5-hydroxytryptamine(5-HT) receptor, and interleukin-6(IL-6) to exert sedative, anxiolytic, and antidepressant effects. Sixty 4-week-old SPF mice were randomly divided into a control group, a model group, a positive drug(diazepam tablets) group, and low-, medium-, and high-dose berberine groups. Medication with corresponding drugs was performed for one week. The results demonstrated that berberine was potent in reducing the activities and standing times of mice, down-regulating the levels of CRP and IL-6 mRNA in the hypothalamus, and up-regulating the expression of 5-HT(P<0.01); however, no significant effect on ESR1 was observed. The network of Euodiae Fructus in treating insomnia was constructed by network pharmacology and verified by tests. The findings indicated that the therapeutic efficacy of Euodiae Fructus in treating insomnia was achieved by participating in multiple biological processes, such as neurotransmitter receptor activity, which provided a scientific basis for its clinical application.
